Therapeutic Exploratory (Phase II)

3,454 trials 1,368 recruiting

Filter these 3,454 trials by condition, country, sponsor and more.

Open in Search →

Breaking the big Five Barriers of Brain Metastasis: A prospective phase II, open-label, multi-center trial of combined nivolumab, ipilimumab… Ended

2024-512684-31-00 non-squamous nonsmall-cell lung cancer (NSCLC) metastat 2021-04-14
Please refer to the full title. Ended

2024-516549-37-00 Treatment of Parkinson’s disease (PD) 2021-04-12
A Study of TL-895 in Myelofibrosis, Indolent Systemic Mastocytosis, Monoclonal Mast Cell Activation Syndrome, or Non-Monoclonal Mast Cell Ac… Ended

2024-514467-26-00 Indolent Systemic Mastocytosis 2021-04-07
A phase II trial of neoadjuvant REGorafenib in combination with nIvolumab and short-course radiotherapy iN intermediate-risk, stage II-III r… Ended

2024-516554-22-00 Locally-advanced stage II-III rectal cancer 2021-03-29
IMMUNOGAST: An umbrella phase 2 trial to assess personalized targeted IMMUNOtherapy-based regimens in recurrent advanced/metastatic GASTric … Ended

2024-517816-31-00 For patients with advanced/metastatic gastric adenocarc 2021-03-19
Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS) Ended

2024-512028-12-00 Advanced ROS1-positive non-small cell lung cancer 2021-03-19
MITO 25.1: A randomized, molecular driven phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucapar… Ended

2024-516632-99-00 Advanced (stage III B-C-IV) ovarian, primary peritoneal 2021-03-17
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cance… Ended

2022-502600-79-00 Endometrial cancer 2021-03-16
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study Ended

2023-507418-28-00 Solid tumors 2021-03-15
Pre- and post-menopausal women or men with advanced (loco-regionally recurrent not amenable to curative therapy or metastatic) HER2-positive… Ended

2023-508829-28-00 Pre- and post-menopausal women or men with advanced (lo 2021-03-15
PEMbrolizumab Plus Lenvatinib In Second Line And Third Line Malignant Pleural MEsotheLiomA Patients: A Single Arm Phase II Study (PEMMELA). Ended

2024-516618-39-00 malignant pleural mesothelioma 2021-02-25
A Phase II clinical trial comparing the efficacy of RO7198457 versus watchful waiting in patients with ctDNA positive, resected Stage II (hi… Ended

2023-509516-28-00 Stage II/Stage III rectal cancer or Stage II (high risk 2021-02-22
Iberdomide as maintenance therapy after autologous stem cell transplantation in newly diagnosed multiple myeloma patients Ended

2024-512354-21-00 Newly diagnosed multiple myeloma 2021-02-22
A phase 1/2, dose and schedule evaluation study to investigate the safety and clinical activity of Belantamab Mafodotin administered in comb… Ended

2024-515988-55-00 Newly diagnosed multiple myeloma 2021-02-22
Exploratory study evaluating the potential of immune signature profiling for predicting response in patients with resectable Stage II, IIIA … Ended

2024-516590-75-00 Lung cancer 2021-02-22
Patritumab Deruxtecan in Subjects with Metastatic or Locally Advanced EGFR-mutated NSCLC Ended

2024-512238-13-00 Metastatic or Locally Advanced EGFR mutated Non-Small C 2021-02-10
A phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with Tafasitamab (MOR208) for patients aggressive Lymphoma. Ended

2024-514775-17-00 Malignant B-cell lymphoma 2021-02-10
FIBRAPLO - Haplo-identical transplantation in patients with myleofibrosis Ended

2024-513325-23-00 Myelofibrosis 2021-02-03
Tiratricol treatment of children with Monocarboxylate Transporter 8 deficiency: Triac Trial II Ended

2024-516123-13-00 Monocarboxylate Transporter 8 (MCT8) deficiency 2021-02-03
A roll-over study with rilpivirine for human immunodeficiency virus type 1 (HIV-1) infected subjects who participated in rilpivirine pediatr… Ended

2024-512889-33-00 HIV-1 Infection 2021-01-30
KILT - A RANDOMIZED NON COMPARATIVE PHASE II STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX ALONE IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERA… Ended

2024-513252-15-00 IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERAL T-CELL 2021-01-28
Efficacy and safety of Carfilzomib in combination with Ibrutinib vs. Ibrutinib alone in Waldenström’s Macroglobulinemia (CZAR-1) Ended

2024-511929-60-00 Waldenström’s Macroglobulinemia 2021-01-28
Encorafenib in combination with Binimetinib in Patients with BRAFV600E mutant metastatic Lung Cancer Ended

2024-515944-22-00 BRAFV600E-mutant metastatic Non-small Cell Lung Cancer 2021-01-19
A phase II, open-label study improving compliance and time of treatment after obtaining complete response through a tailored schedule of son… Ended

2024-516797-29-00 locally advanced basal cell carcinoma 2021-01-12